In a study by Matsuo et al. [58], nearly 25% of male patients with diabetes who were treated with a PDE5 inhibitors for LUTSs found no benefit, and the respective percentage in non-diabetic patients was 0%. This evidence concerns the gene PDE5A and diabetes mellitus.